Pyrazole-based cathepsin S inhibitors with improved cellular potency.

High potency pyrazole-based noncovalent inhibitors of human cathepsin S (CatS) were developed by modification of the benzo-fused 5-membered ring heterocycles found in earlier series of CatS inhibitors. Although substitutions on this heterocyclic framework had a moderate impact on enzymatic potency, dramatic effects on cellular activity were observed. Optimization afforded indole- and benzothiophene-derived analogues that were high affinity CatS inhibitors (IC(50)=20-40 nM) with good cellular potency (IC(50)=30-340 nM).

[1]  Vincent Leroy,et al.  Cathepsin S inhibitors , 2004 .

[2]  Yoshifumi Watanabe,et al.  Syntheses of 4-(benzo[b]furan-2 or 3-yl)- and 4-(benzo[b]-thiophen-3-yl)piperidines with 5-HT2 antagonist activity , 1993 .

[3]  Lars Karlsson,et al.  Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[5]  E. Altmann,et al.  Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents. , 2003, Bioorganic & medicinal chemistry letters.

[6]  M. Blaskovich,et al.  Recent discovery and development of protein tyrosine phosphatase inhibitors , 2002 .

[7]  Mary Pat Beavers,et al.  Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. , 2004, Journal of medicinal chemistry.

[8]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[9]  S. Bevan,et al.  Role of the cysteine protease cathepsin S in neuropathic hyperalgesia , 2007, PAIN.

[10]  Jennifer L. Harris,et al.  Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl. , 2006, Bioorganic & Medicinal Chemistry Letters.

[11]  A. Rudensky,et al.  The role of lysosomal proteinases in MHC class Il‐mediated antigen processing and presentation , 1999, Immunological reviews.

[12]  Wen Jiang,et al.  Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[13]  Jun Li,et al.  Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3. , 2006, Bioorganic & medicinal chemistry letters.

[14]  Cheryl A. Grice,et al.  The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Jennifer L. Harris,et al.  Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1. , 2005, Bioorganic & medicinal chemistry letters.

[16]  J. Falgueyret,et al.  Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. , 2005, Journal of medicinal chemistry.

[17]  W. Jahnke,et al.  Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. , 2002, Journal of medicinal chemistry.

[18]  Kooil Kang,et al.  Recent developments of cathepsin inhibitors and their selectivity , 2002 .

[19]  J. Deussing,et al.  Proteases involved in MHC dass II antigen presentation , 1999, Immunological reviews.